Traws Pharma Appoints New Director
Ticker: TRAW · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Traws Pharma adds Dr. Deitcher to the board, effective 6/17.
AI Summary
Traws Pharma, Inc. announced on June 17, 2024, a change in its board of directors. Specifically, Dr. Steven A. Deitcher has been appointed as a new director. The company, formerly known as Onconova Therapeutics, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Dr. Steven A. Deitcher (person) — Appointed Director
- Onconova Therapeutics, Inc. (company) — Former Company Name
- June 17, 2024 (date) — Date of earliest event reported
FAQ
Who was appointed as a new director to Traws Pharma, Inc.'s board?
Dr. Steven A. Deitcher was appointed as a new director.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 17, 2024.
What was Traws Pharma, Inc. formerly known as?
Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.
In which state is Traws Pharma, Inc. incorporated?
Traws Pharma, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification code for Traws Pharma, Inc.?
The Standard Industrial Classification code for Traws Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-21 17:21:09
Filing Documents
- tm2417729d1_8k.htm (8-K) — 24KB
- 0001104659-24-074003.txt ( ) — 191KB
- tmb-20240617.xsd (EX-101.SCH) — 3KB
- tmb-20240617_lab.xml (EX-101.LAB) — 33KB
- tmb-20240617_pre.xml (EX-101.PRE) — 22KB
- tm2417729d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 17, 2024, Steven M. Fruchtman informed the board of directors (the "Board") of Traws Pharma, Inc. (the "Company") of his intent to resign from his positions of President and Chief Scientific Officer, Oncology. On June 17, 2024, Dr. Fruchtman's attorney provided a letter to the Company's counsel, which indicates that Dr. Fruchtman believes his resignation to be for "good reason" under the terms of his employment agreement and his expectation of severance compensation commensurate therewith and in connection with a change in control. The Board has accepted Dr. Fruchtman's resignation effective immediately but disagrees with the characterization of the events set forth in the letter and accordingly believes that no severance payments are due to Dr. Fruchtman under the terms of his employment agreement. Victor Moyo continues as the Company's Chief Medical Officer, Oncology.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRAWS PHARMA, Inc. Date: June 21, 2024 By: /s/ MARK GUERIN Mark Guerin Chief Financial Officer